From evidence to action
At ICARS, our mission is to partner with Low- and Middle-income countries (LMICs) in their efforts to reduce drug-resistant infections.
We do this by co-developing tailored solutions with LMIC governments and researchers, who then implement them on the ground using ICARS funding and expertise, building on AMR National Action Plans.
Follow us and view our latest news
ICARS Annual Report 2022
Over the past three years, ICARS has gone through significant development and matured as an organisation. To celebrate key achievements and demonstrate the broad scope of ICARS’ efforts, the ICARS 2022 annual report features research, policy, and event highlights across ICARS’ five interconnected strategic pillars (testing solutions, translating evidence, advocacy, capacity building, and developing trusting partnerships).
ICARS Strategy 2022 – 2026
Guided by our vision of a world without drug-resistant infections, we have developed a new strategy with a revised outcome framework and refined the scope and goals of each of our interconnected pillars.
We are pleased to present a succinct overview of ICARS unique value proposition, followed by our overarching strategy that will run until 2026, as well as a roadmap that details our planned activities per pillar.
Our projects inform policy and practice around the world
At ICARS, we simultaneously use top-down and bottom-up approaches, engaging with government ministries while involving scientists and practitioners throughout the process.
Join our mission
To achieve sustainable change in LMICs, we invite countries and foundations to join us as Strategic Funding Partners, Funding Partners or Mission Partners, in a truly international effort to mitigate antimicrobial resistance.
Please do not hesitate to contact our team for further information.
